Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2013
|
| gptkbp:ATCCode |
C02KX05
|
| gptkbp:brand |
gptkb:Adempas
|
| gptkbp:CASNumber |
625115-55-1
|
| gptkbp:chemicalFormula |
C20H19FN8O2
|
| gptkbp:contraindication |
pregnancy
concomitant use with PDE5 inhibitors concomitant use with nitrates |
| gptkbp:drugClass |
vasodilator
soluble guanylate cyclase stimulator |
| gptkbp:genericName |
riociguat
|
| https://www.w3.org/2000/01/rdf-schema#label |
Adempas
|
| gptkbp:indication |
pulmonary arterial hypertension
chronic thromboembolic pulmonary hypertension |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bayer
|
| gptkbp:mechanismOfAction |
soluble guanylate cyclase stimulator
|
| gptkbp:pregnancyCategory |
X (contraindicated)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness headache hypotension dyspepsia |
| gptkbp:bfsParent |
gptkb:Bayer_HealthCare_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|